Co-Founder, President and CEOLinkedIn →
Grannus therapeutics is overcoming previous limitations to Hsp90 inhibitors and ushering in a new wave of cancer treatment.
By selectively inhibiting Hsp90β, Grannus has eliminated the toxicity and dosing challenges of previous pan-inhibitors.
The Hsp90 chaperone proteins is an attractive oncology target with potential across multiple tumor types. Since the early 2000s, more than 20 molecules have been investigated in clinical trials, many of which were sponsored by major pharma companies. Unfortunately, to date none have received FDA approval, due to on-target toxicities and disappointing efficacy results. All these failed trials utilized pan inhibitors that targeted all four isoforms of Hsp90: alpha, beta, GRp94, and Trap-1.
Grannus has overcome the limitations and failures of previous Hsp90 inhibitors, through the breakthrough development of the first-in-class Hsp90𝛽-selective inhibitor. With clean toxicity profiles and demonstrated in-vivo efficacy, Grannus is poised to bring a new treatment option to patients in need across multiple solid tumors.
Grannus is a biotech startup based on the technological discoveries of Notre Dame Scientists Dr. Brian Blagg and Dr. Sanket Mishra, and the administration of biotech executive John Foglesong.
The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition
Journal of Medicinal ChemistryRead More →
The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking
Molecular PharmaceuticsRead More →
The molecular chaperone Hsp90α deficiency causes retinal degeneration by disrupting Golgi organization and vesicle transportation in photoreceptors
Journal of Molecular Cell BiologyRead More →
Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors
Frontiers in ImmunologyRead More →